Furthermore, GA-MSCs have the potential to differentiate into pericytes and maintain tumor vascular structure, and the GA-MSCs with CD90 low expression show a more active angiogenic capacity, which contribute to glioma progression [10, 30]. The gene discussed is THY1; the disease is glioma.